Novel OMV vaccine platform for quick response to Disease X

新型 OMV 疫苗平台可快速应对 X 病

• 批准号: 10087303
• 金额: $ 231.42万
• 依托单位: ABERA BIOSCIENCE AB
• 依托单位国家: 英国
• 项目类别: Small Business Research Initiative
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10087303
• 关键词: Novel; OMV; vaccine; platform; quick

Abera's vaccine platform enables display of multiple antigens on Outer Membrane Vesicles (OMVs) through covalent-based coupling. These OMV nanoparticles possess inherent adjuvant activity, which elicits robust humoral and cellular immune responses. The primary objective of this project is to expedite the development of a rapid responsive platform for development of vaccines against outbreaks of Disease X. These vaccines are characterized by their exceptional efficiency, rapid development process, cost-effective production, streamlined logistics without the need for cold chain, and swift interruption of disease transmission.Our aim is to establish a production process to stockpile OMVs, enabling their prompt coupling to antigens during times of pandemics. This approach will accelerate vaccine development and ensure equitable access to vaccines, particularly in LMICs and ODA countries. Leveraging straightforward and robust technologies, production will be cost-effective and easily transferable across global regions. Notably, the compatibility of these vaccines with needle-free intranasal administration offers a unique advantage in combatting airborne disease outbreaks, where curbing transmission is of paramount importance. OMVs exhibit inherent stability, even under elevated temperatures. To further enhance stability and improve vaccine accessibility by eliminating the need for cold chain storage and distribution, we intend to implement lyophilisation.Our plan involves producing relevant batches of OMVs at a suitable process scale to demonstrate consistency and stability in stockpiles. Additionally, we will develop an analytical package to assess the capacity and consistency of antigen coupling in batches subjected to extended storage. Furthermore, we will evaluate the induction of appropriate immune responses. Moreover, we plan to establish a regulatory strategy for fast approval of a new vaccine based on the platform in case of a pandemic outbreak.In conclusion, Abera's vaccine platform, with its OMV-based technology, promises to revolutionize vaccine development. By establishing a production process for OMV stockpiles and ensuring their consistency and stability, we can swiftly respond to outbreaks, while also enabling widespread and equitable access to vaccines, even in resource-constrained settings. Through these efforts, we aim to create a comprehensive regulatory framework that expedites the approval of new vaccines during pandemics.

Abera的疫苗平台能够通过基于共价的偶联在外膜囊泡（OMV）上展示多种抗原。这些OMV纳米颗粒具有固有的佐剂活性，这激发了强大的体液和细胞免疫应答。该项目的主要目标是加快开发一个快速反应平台，用于开发预防X疾病爆发的疫苗。这些疫苗的特点是效率高、开发速度快、生产成本低、物流流程简单、无需冷链、能迅速阻断疾病传播。我们的目标是建立一个储存OMV的生产流程，使其在大流行时能迅速与抗原结合。这一办法将加快疫苗开发，确保公平获得疫苗，特别是在中低收入国家和官方发展援助国家。利用简单而强大的技术，生产将具有成本效益，并易于在全球区域之间转移。值得注意的是，这些疫苗与无针鼻内给药的相容性在对抗空气传播疾病爆发方面提供了独特的优势，其中抑制传播至关重要。即使在高温下，OMV也表现出固有的稳定性。为进一步加强疫苗的稳定性，并透过消除冷链储存和分销的需要，提高疫苗的可及性，我们计划实施冷冻干燥。我们的计划包括以适当的工艺规模生产相关批次的OMV，以证明库存的一致性和稳定性。此外，我们将开发一个分析包，以评估延长储存批次中抗原偶联的能力和一致性。此外，我们将评估适当免疫应答的诱导。此外，我们计划建立一个监管策略，以便在大流行爆发的情况下，快速批准基于该平台的新疫苗。总之，Abera的疫苗平台及其基于OMV的技术，有望彻底改变疫苗开发。通过建立OMV库存的生产流程并确保其一致性和稳定性，我们可以迅速应对疫情，同时即使在资源有限的情况下也能广泛和公平地获得疫苗。通过这些努力，我们的目标是建立一个全面的监管框架，在大流行期间加快新疫苗的批准。